Business Wire

The Body Shop Switzerland Transforms the Shopping Experience with Axway


The Body Shop, an international beauty business, is leveraging Axway (Paris:AXW) (Euronext: AXW.PA), a catalyst for digital transformation, to improve the customer experience at retail stores throughout Switzerland. With Axway Appcelerator, The Body Shop has been able to rethink its customer loyalty program, integrate massive amounts of data, and successfully implement an innovative new mobile application to increase in-store purchases. The new Axway-powered Love Your Body Club mobile app has enabled The Body Shop to deliver personalized and contextualized experience to more than 90,000 customers in Switzerland.

Formed in 1976, The Body Shop is an international, ethical beauty business that sells more than 900 different beauty products in 2,600 stores worldwide and online. To build on its successful business in Switzerland and enhance the experience it offers to customers in the country, The Body Shop worked with Axway to completely revamp its Love Your Body Club customer loyalty program. Available on iOS and Android, the new Axway-powered Love Your Body Club mobile app uses Dashboard API to let shoppers receive tailored offers, earn vouchers, get invited to special events, shop for products, view their purchase history and locate stores. By tapping into internal and external data using a cohesive customer experience network, the innovative new app can deliver contextualized experiences by notifying loyalty program members of offers as they near a store. If customers are interested, the app presents a QR code that can be redeemed at checkout or a voucher that can be redeemed online.

“We have always been committed to providing our customers with the best possible shopping experience,” said Angelika Lanen, CEO, The Body Shop. “By working with Axway to leverage the latest mobile innovations, we have been able to successfully transform our Love Your Body Club program and give our customers across Switzerland a truly unique shopping experience.”

With Axway Appcelerator, The Body Shop was able to meet unique needs of the Swiss market where multiple languages are spoken. By incorporating a simple in-app language switching that doesn’t require changing mobile device system settings, the app enables The Body Shop to provide shoppers with a seamless and efficient shopping experience. Via the Analytics API, The Body Shop can also track app opens, session lengths, device use, and pinpoint the customer’s region – components useful in improving the individual customized experience.

The Body Shop was also able to streamline the checkout process by temporarily auto-adjusting the user’s screen brightness for easy scanning of QR codes by the point-of-sale system. In addition, in-store staff can view and repurchase recently bought items for customers to accelerate checkout times.

“Many of our customers look at providing immersive customer experiences by building great apps that can run on a range of different devices while connecting to massive amounts of backend data,” said Hendrik Unkenholz, Head of Development at Smilla AG, digital agency responsible for development of The BodyShop app. “Thanks to Axway Appcelerator, we could develop the innovative app for The Body Shop with significantly decreased development time, without compromising the ability to support the app anywhere on any device. In addition, with Appcelerator, we could maintain the app on a single codebase, saving both time and money.”

“Axway Appcelerator has enabled The Body Shop to build new digital engagement models in order to meet skyrocketing customer expectations,” said Nick Ferrante, executive vice president global sales, Axway. “With Axway Appcelerator, The Body Shop has been able to unlock the value of data in order to anticipate and adapt to changing customer expectations by quickly designing a differentiated mobile app that improves the shopping experience and ultimately drives brand loyalty and sales.”

Twitter: @Axway

About Axway
Axway (Euronext: AXW.PA) is a catalyst for transformation. With Axway AMPLIFY™, our cloud-enabled data integration and engagement platform, digital leaders anticipate, adapt and scale to meet rising customer expectations. Our unified, API-first approach connects data from anywhere, heightens collaboration, fuels millions of apps and delivers real-time analytics to build customer experience networks. From idea to execution, we help make the future possible for more than 11,000 organizations in 100 countries. To learn more, visit

About The Body Shop
Founded in 1976 in Brighton, England, by Anita Roddick, The Body Shop is a global beauty brand. The Body Shop seeks to make a positive difference in the world by offering high-quality, naturally-inspired skincare, hair care and make-up produced ethically and sustainably. The Body Shop pioneered the philosophy that business can be a force for good and this ethos is still the brand’s driving force.

Contact information

Blanc & Otus
Simon Jones, 415-856-5155

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28Tiedote

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05Tiedote

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme